Equities Analysts Issue Forecasts for IDYA Q1 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of IDEAYA Biosciences in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($0.66) per share for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.45) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($2.74) EPS, FY2026 earnings at ($2.81) EPS and FY2027 earnings at ($2.70) EPS.

Several other equities research analysts have also commented on the stock. Oppenheimer restated an “outperform” rating and issued a $53.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Wedbush reaffirmed an “outperform” rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Leerink Partners cut IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Stephens assumed coverage on shares of IDEAYA Biosciences in a report on Monday, November 18th. They issued an “overweight” rating and a $51.00 target price for the company. Finally, UBS Group began coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They issued a “buy” rating and a $50.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.67.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock opened at $21.38 on Monday. IDEAYA Biosciences has a fifty-two week low of $21.10 and a fifty-two week high of $47.74. The company has a market capitalization of $1.85 billion, a PE ratio of -9.18 and a beta of 0.82. The company has a 50 day moving average price of $24.84 and a 200-day moving average price of $30.38.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP grew its position in shares of IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 800 shares during the period. Covestor Ltd boosted its position in IDEAYA Biosciences by 23,050.0% during the third quarter. Covestor Ltd now owns 926 shares of the company’s stock worth $29,000 after purchasing an additional 922 shares in the last quarter. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the fourth quarter valued at approximately $35,000. US Bancorp DE increased its position in shares of IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after buying an additional 689 shares in the last quarter. Finally, KBC Group NV raised its stake in shares of IDEAYA Biosciences by 29.1% during the 3rd quarter. KBC Group NV now owns 2,274 shares of the company’s stock worth $72,000 after buying an additional 513 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.